Long-Term Activity of Vemurafenib in Patients With BRAF-Mutated Advanced Cancers Other Than BRAFV600-Mutated Melanoma and NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma
ESMO Open 2023 Nov 01;8(6)102038, JY Blay, C Cropet, S Mansard, Y Loriot, C De La Fouchardière, J Haroche, D Topart, D Tougeron, B You, A Italiano, V Le Brun-Ly, JM Ferrero, N Penel, M Fabbro, X Troussard, D Malka, I Ray-Coquard, S Leboulleux, A Fléchon, E Maubec, J Charles, S Dalle, S Taieb, GCTE Garcia, AM Mandache, N Colignon, M Gavrel, F Nowak, N Hoog Labouret, C Mahier Aït Oukhatar, C Gomez-RocaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.